ISIS and GENZ meet trial goal; ISIS stock sells off
Clinical Profile concerns spur a big sell-off : ISIS shares down 14.6% to $9.40 on volume of 10.6M shares The Mipomersen Phase 3 study in patients with Heterozygous Familial Hypochesterolemia, a genetic disorder, met its primary endpoint but investors were worried about potential side effects...
New Coverage: genomics and diagnostics-Genomic Health(GHDX)
Genomic Health (GHDX) 2/4/10 Molecular Diagnostics and Genomics Public Company- Market Cap $482M Stock Price $16.5-17.5 Summary Genomic Health is a life science Company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow...
Microfluidics (MFLU.OB-$0.90) -a leader in advanced nano-material processing for a variety of industries
Microfluidics (MFLU.OB-$0.90) -a leader in advanced, nano-material, processing for a variety of industries A turn-around play with value characteristics This is a "heads-up" on a special report that we will issue post-earnings within two weeks on the nanotechnology small cap Microfluidics...
Life Science Sector Performance: ETF’s and Funds Feb 12 mos.YTD
In a volatile sell-off day involving tech stocks, the biotech world was relatively calm. Despite good news on corporate earnings and a GDP with an annual 5.7% annual growth, investors chose to take profits even on solid player like Microsoft down over 3% today. Market Strength is routinely...
Biomedical stocks beat the bleak
Large Cap biomedical stocks held firm on another volatile but down day in the market driven by a host of macro and fundamental factors: earnings, Davos, Greece,China, politics, Bernanke confirmation, strong dollar, jobs, etc. In this convoluted market the technology leader Apple ( PE 26.6,EPS...